Alector (ALEC) Competitors $2.15 +0.69 (+47.26%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$2.14 0.00 (-0.23%) As of 08/8/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ALEC vs. RLAY, BCAX, VECT, TLRY, ORGO, XNCR, MRVI, TSHA, TRML, and BCYCShould you be buying Alector stock or one of its competitors? The main competitors of Alector include Relay Therapeutics (RLAY), Bicara Therapeutics (BCAX), VectivBio (VECT), Tilray Brands (TLRY), Organogenesis (ORGO), Xencor (XNCR), Maravai LifeSciences (MRVI), Taysha Gene Therapies (TSHA), Tourmaline Bio (TRML), and Bicycle Therapeutics (BCYC). These companies are all part of the "pharmaceutical products" industry. Alector vs. Its Competitors Relay Therapeutics Bicara Therapeutics VectivBio Tilray Brands Organogenesis Xencor Maravai LifeSciences Taysha Gene Therapies Tourmaline Bio Bicycle Therapeutics Relay Therapeutics (NASDAQ:RLAY) and Alector (NASDAQ:ALEC) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk, media sentiment and dividends. Is RLAY or ALEC more profitable? Relay Therapeutics has a net margin of 0.00% compared to Alector's net margin of -142.10%. Relay Therapeutics' return on equity of -39.98% beat Alector's return on equity.Company Net Margins Return on Equity Return on Assets Relay TherapeuticsN/A -39.98% -35.94% Alector -142.10%-101.62%-24.84% Which has better valuation & earnings, RLAY or ALEC? Alector has higher revenue and earnings than Relay Therapeutics. Alector is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRelay Therapeutics$7.68M71.89-$337.71M-$1.95-1.65Alector$100.56M2.14-$119.05M-$1.26-1.71 Do analysts prefer RLAY or ALEC? Relay Therapeutics currently has a consensus price target of $17.25, indicating a potential upside of 435.71%. Alector has a consensus price target of $4.17, indicating a potential upside of 93.80%. Given Relay Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Relay Therapeutics is more favorable than Alector.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Relay Therapeutics 0 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.92Alector 2 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.29 Does the media favor RLAY or ALEC? In the previous week, Relay Therapeutics had 3 more articles in the media than Alector. MarketBeat recorded 11 mentions for Relay Therapeutics and 8 mentions for Alector. Alector's average media sentiment score of 0.31 beat Relay Therapeutics' score of 0.04 indicating that Alector is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relay Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral Alector 1 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, RLAY or ALEC? Relay Therapeutics has a beta of 1.62, suggesting that its stock price is 62% more volatile than the S&P 500. Comparatively, Alector has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500. Do institutionals and insiders have more ownership in RLAY or ALEC? 97.0% of Relay Therapeutics shares are held by institutional investors. Comparatively, 85.8% of Alector shares are held by institutional investors. 4.9% of Relay Therapeutics shares are held by insiders. Comparatively, 9.1% of Alector shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. SummaryRelay Therapeutics beats Alector on 11 of the 17 factors compared between the two stocks. Get Alector News Delivered to You Automatically Sign up to receive the latest news and ratings for ALEC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALEC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALEC vs. The Competition Export to ExcelMetricAlectorMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$214.98M$3.00B$5.53B$9.71BDividend YieldN/A2.44%4.60%4.12%P/E Ratio-1.8517.2130.0624.80Price / Sales2.14290.78427.92188.61Price / CashN/A41.7736.7758.47Price / Book1.677.328.195.60Net Income-$119.05M-$54.48M$3.27B$266.27M7 Day Performance48.28%0.01%6.14%5.08%1 Month Performance25.00%0.64%0.07%0.61%1 Year Performance-57.68%8.71%36.43%22.83% Alector Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALECAlector4.043 of 5 stars$2.15+47.3%$4.17+93.8%-57.7%$214.98M$100.56M-1.85270News CoverageEarnings ReportGap UpHigh Trading VolumeRLAYRelay Therapeutics1.9558 of 5 stars$3.36-4.5%$17.67+425.8%-51.9%$576.06M$7.68M-1.51330News CoverageEarnings ReportAnalyst ForecastGap DownBCAXBicara Therapeutics2.0258 of 5 stars$10.53-5.2%$31.86+202.6%N/A$574.26MN/A0.0032News CoveragePositive NewsUpcoming EarningsVECTVectivBioN/A$16.85flatN/AN/A$573.24M$27.34M0.0030High Trading VolumeTLRYTilray Brands3.0351 of 5 stars$0.57-2.1%$1.92+237.0%-63.8%$572.40M$821.31M-0.252,650Options VolumeORGOOrganogenesis4.2936 of 5 stars$4.51-2.4%$6.50+44.1%+78.4%$572.09M$482.04M-26.53950News CoverageEarnings ReportAnalyst ForecastGap DownXNCRXencor3.4644 of 5 stars$7.98-4.1%$28.00+250.9%-54.9%$567.94M$110.49M-2.61280News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionMRVIMaravai LifeSciences3.6142 of 5 stars$2.22-5.1%$6.64+199.0%-74.2%$565.35M$241.86M-1.95610News CoverageUpcoming EarningsOptions VolumeGap DownTSHATaysha Gene Therapies2.9723 of 5 stars$2.63-3.7%$8.17+210.5%+30.1%$564.56M$7.22M-7.74180Upcoming EarningsTRMLTourmaline Bio1.8737 of 5 stars$21.76-1.7%$49.33+126.7%+48.3%$558.80MN/A-6.7844News CoverageUpcoming EarningsBCYCBicycle Therapeutics3.3911 of 5 stars$7.99-6.2%$24.22+203.2%-67.0%$553.31M$35.28M-2.54240News CoveragePositive NewsEarnings Report Related Companies and Tools Related Companies Relay Therapeutics Alternatives Bicara Therapeutics Alternatives VectivBio Alternatives Tilray Brands Alternatives Organogenesis Alternatives Xencor Alternatives Maravai LifeSciences Alternatives Taysha Gene Therapies Alternatives Tourmaline Bio Alternatives Bicycle Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALEC) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 17th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alector, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alector With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALEC Stock Alerts